Monoamine oxidase inhibitor

A monoamine oxidase inhibitor (MAOI) is a substance that blocks monoamine oxidase, the flavin-containing enzyme that breaks down serotonin, dopamine, norepinephrine, and other biogenic amines.^[1] The class is defined by this shared enzymatic action — not by any common chemical scaffold — so its members share a pharmacological endpoint while differing widely in structure, potency, and selectivity for the two MAO isoforms.^[2]

Across this chemically diverse class, members converge on a single endpoint — reduced enzymatic breakdown of monoamines, allowing serotonin, dopamine, and norepinephrine to accumulate in synaptic clefts and in peripheral tissues.^[2] They reach that endpoint through chemically unrelated routes that differ in isoform selectivity, reversibility, and whether MAO inhibition is the compound's primary action or a secondary one.

Two distinctions matter more than the chemical route. The first is isoform selectivity. MAO-A is concentrated in the gut wall and liver and metabolizes serotonin, norepinephrine, and dietary tyramine; MAO-B preferentially handles phenylethylamine and benzylamine; both metabolize dopamine and tyramine.^[2] Inhibiting MAO-A produces the class's two defining acute dangers — tyramine crisis and serotonin toxicity. Selective MAO-B inhibition does not, because MAO-A retains capacity to clear tyramine.^[2] Every member relevant to this brief inhibits MAO-A meaningfully.

The second is reversibility. Irreversible inhibitors covalently modify the enzyme's FAD cofactor; activity returns only as new enzyme is synthesized, a process of roughly two weeks.^[1] Reversible inhibitors compete at the active site without binding covalently, so blockade falls as plasma drug levels fall — typically over hours.^[4]

Most plant-source beta-carboline members are reversible, which limits but does not eliminate their interaction risk during the active window.^[5] A third clinically important consequence of MAO-A blockade, regardless of the route by which it is achieved, is oral potentiation of tryptamines: DMT is almost entirely degraded by intestinal MAO-A on first pass and reaches systemic circulation only when MAO-A is inhibited — the pharmacological basis of orally active ayahuasca and changa.^[6]

The class draws members from several chemically unrelated families. The plant-source beta-carbolines, a handful of synthetic phenethylamines, and a substituted tryptamine illustrate the range.

These members differ widely in pharmacological identity and intended use — clinical antidepressant action, ceremonial plant medicine, recreational psychedelic, and forensic toxicology — but every one of them blocks MAO sufficiently to alter monoamine clearance, and each carries some version of the class's interaction risk during its pharmacological window.

Because MAO inhibition is a mechanism rather than an experiential state, the subjective profile of any class member depends heavily on what other actions the compound has. Class-level patterns nonetheless track the magnitude of MAO blockade and the resulting monoamine load.

The same axis — elevation of monoamine tone — drives both the effects sought (mood elevation, oral tryptamine activity) and the dangers (serotonin toxicity, tyramine crisis); the margin between them narrows steeply as additional serotonergic load is added by diet or by a co-administered drug.

The mechanism of tyramine crisis is direct. Normally, MAO-A in the gut wall and liver metabolizes most dietary tyramine before it reaches systemic circulation. When MAO-A is inhibited, tyramine bypasses first-pass elimination, enters the circulation, and displaces stored norepinephrine from sympathetic nerve terminals, producing rapid, severe rises in blood pressure that can culminate in cerebral hemorrhage.^[10]

The relevant dietary categories are aged and fermented cheeses, cured and fermented meats, draft beer, soy products, and concentrated yeast extracts. Reversible beta-carboline inhibitors carry less tyramine risk than irreversible pharmaceutical MAOIs, but dietary caution remains warranted during the active pharmacological window.^[5]

Serotonin toxicity arises when MAO-A blockade prevents clearance of serotonin at the same moment another mechanism is increasing serotonergic input. The Hunter Serotonin Toxicity Criteria — clonus, agitation with diaphoresis, tremor with hyperreflexia, and hypertonia with fever — are the clinical framework for diagnosis.^[9]

Reported fatalities in recreational contexts involving class members include deaths attributed to PMA, PMMA, and 2C-T-7, typically when these compounds were taken alongside MDMA or other serotonergics; the convergence of release and impaired clearance generates rapidly escalating toxicity. The sibling class of monoamine releasing agents is the single highest-risk co-administration scenario for any MAOI member.

Tolerance & dependence

MAOIs do not produce the receptor-downregulation tolerance characteristic of opioids or CNS depressants, and physical dependence with a discrete, dangerous withdrawal syndrome is not a class feature.^[3] Some clinical users develop tolerance to the antidepressant effect over time, but this is not universal and is not a consistent feature of reversible beta-carboline use in ceremonial contexts.

A discontinuation syndrome is, however, documented for pharmaceutical MAOIs and likely extends to any member used regularly at significant doses. Symptoms on abrupt cessation can include dizziness, nausea, irritability, insomnia, anxiety, paresthesias, and — rarely — seizures or psychosis.^[1]

Cross-tolerance at the level of MAO inhibition has not been well characterized in the literature, but because tyramine crisis and serotonin toxicity are acute pharmacodynamic events rather than tolerance-mediated phenomena, tolerance to one MAOI's subjective effects does not protect against the interaction risks of co-exposure to another.

MAOIs sit within the broader pharmacological category of substances that modulate the monoamine system. Within that parent category, MAOIs are the degradation-inhibition branch — separate from reuptake inhibition (SSRIs, SNRIs, tricyclic antidepressants) and from monoamine release. Each branch arrives at elevated synaptic monoamine concentrations by a different route.

The sibling class in this dimension — monoamine releasing agents — is the most important contrast. Releasers raise synaptic monoamines by reversing transporter direction or triggering vesicular release; MAOIs raise them by blocking enzymatic clearance. The mechanisms are independent, and combining them is supra-additive: one floods the synapse with serotonin while the other prevents its removal.

This combination underlies the lethality seen with PMA and PMMA (members of this class that are themselves releasers) and is the reason co-administration of any MAOI with MDMA, methamphetamine, or other amphetamines carries acute fatality risk even at individually non-lethal doses.

The class is also functionally distinct from monoamine reuptake inhibitors: both elevate synaptic monoamines, but reuptake inhibitors block transporter-mediated clearance from the cleft while MAOIs block intracellular enzymatic degradation. Combining MAOIs with reuptake inhibitors generates the same high serotonin syndrome risk seen with releaser co-administration, which is why MAOI–SSRI combination is an absolute contraindication in clinical practice.^[1]

The takeaway across all three contrasts is simple: any agent that increases serotonergic signaling — by release, by reuptake inhibition, by precursor loading, or by another MAO inhibitor — stacks dangerously onto an active MAOI member.